myelofibrosis
MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment
January 31, 2024Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …
MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
November 23, 2023Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment
November 13, 2023Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis
GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia
September 18, 2023Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …
Myelofibrosis market to increase to be worth over $1 billion by 2025
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis
The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …
Bristol-Myers Squibb makes big pharma deals
September 1, 2015Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis
Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …
Novartis’ myelofibrosis treatment approved in Europe
August 28, 2012Sales and Marketing Incyte, Jakavi, Novartis, Orphan Drugs, myelofibrosis
Novartis’ Jakavi, a new treatment for patients with myelofibrosis has been approved in Europe. The drug was co-developed with Incyte, …
Novartis plans Q2 filing for blood cancer drug
March 17, 2011Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib
Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …
Novartis blood cancer drug impresses in late stage trial
December 22, 2010Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug
Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …
